These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 20176990)

  • 21. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
    Roig E; Perez-Villa F; Morales M; Jiménez W; Orús J; Heras M; Sanz G
    Eur Heart J; 2000 Jan; 21(1):53-7. PubMed ID: 10610744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
    Sigurdsson A
    Blood Press Suppl; 1995; 1():1-45. PubMed ID: 7599749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and prognosis associated with a preserved left ventricular systolic function in a large cohort of congestive heart failure outpatients managed by cardiologists. Data from the Italian Network on Congestive Heart Failure.
    Tarantini L; Faggiano P; Senni M; Lucci D; Bertoli D; Porcu M; Opasich C; Tavazzi L; Maggioni AP
    Ital Heart J; 2002 Nov; 3(11):656-64. PubMed ID: 12506524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The use of beta blockers in heart failure: clinical studies].
    Cobelli F
    Ital Heart J Suppl; 2000 Aug; 1(8):996-1002. PubMed ID: 10993005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF).
    Fonarow GC; Albert NM; Curtis AB; Stough WG; Gheorghiade M; Heywood JT; McBride ML; Inge PJ; Mehra MR; O'Connor CM; Reynolds D; Walsh MN; Yancy CW
    Circulation; 2010 Aug; 122(6):585-96. PubMed ID: 20660805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic ambulatory intracardiac pressures and future heart failure events.
    Stevenson LW; Zile M; Bennett TD; Kueffer FJ; Jessup ML; Adamson P; Abraham WT; Manda V; Bourge RC
    Circ Heart Fail; 2010 Sep; 3(5):580-7. PubMed ID: 20562255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
    Mantziari L; Guha K; Khalique Z; McDonagh T; Sharma R
    Am J Cardiol; 2012 Jun; 109(11):1619-25. PubMed ID: 22465318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of cardiac troponin T elevation is independent of renal function and clinical findings in heart failure patients.
    Orea-Tejeda A; Sánchez-González LR; Castillo-Martínez L; Valdespino-Trejo A; Sánchez-Santillán RN; Keirns-Davies C; Colín-Ramírez E; Montańo-Hernández P; Dorantes-García J
    Cardiol J; 2010; 17(1):42-8. PubMed ID: 20104456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B-type natriuretic peptide. Guided vs. conventional care in outpatients with chronic heart failure: a retrospective study.
    De Vecchis R; Esposito C; Di Biase G; Ariano C
    Minerva Cardioangiol; 2013 Aug; 61(4):437-49. PubMed ID: 23846010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study.
    Eurlings LW; van Pol PE; Kok WE; van Wijk S; Lodewijks-van der Bolt C; Balk AH; Lok DJ; Crijns HJ; van Kraaij DJ; de Jonge N; Meeder JG; Prins M; Pinto YM
    J Am Coll Cardiol; 2010 Dec; 56(25):2090-100. PubMed ID: 21144969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.
    Conraads VM; Spruit MA; Braunschweig F; Cowie MR; Tavazzi L; Borggrefe M; Hill MR; Jacobs S; Gerritse B; van Veldhuisen DJ
    Circ Heart Fail; 2014 Mar; 7(2):279-87. PubMed ID: 24519908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal heart failure therapy and successful cardioversion in heart failure patients with atrial fibrillation.
    Boldt LH; Rolf S; Huemer M; Parwani AS; Luft FC; Dietz R; Haverkamp W
    Am Heart J; 2008 May; 155(5):890-5. PubMed ID: 18440338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment.
    Castel MA; Magnani S; Mont L; Roig E; Tamborero D; Méndez-Zurita F; Femenia JF; Tolosana JM; Pérez-Villa F; Brugada J
    Europace; 2010 Aug; 12(8):1136-40. PubMed ID: 20543199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial.
    Sharma GV; Woods PA; Lindsey N; O'Connell C; Connolly L; Joseph J; McIntyre KM
    J Card Fail; 2011 Sep; 17(9):718-25. PubMed ID: 21872140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of therapy for advanced heart failure.
    Stevenson LW
    Eur J Heart Fail; 2005 Mar; 7(3):323-31. PubMed ID: 15718172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
    Cice G; Di Benedetto A; D'Isa S; D'Andrea A; Marcelli D; Gatti E; Calabrò R
    J Am Coll Cardiol; 2010 Nov; 56(21):1701-8. PubMed ID: 21070920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival: Results From the Valsartan Heart Failure Trial.
    Florea VG; Rector TS; Anand IS; Cohn JN
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27413037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.